At Atara, our mission is to transform the lives of patients with serious diseases through pioneering science, teamwork and a commitment to excellence. We aim to offer hope to people whose lives have been impacted by cancer and autoimmune diseases.
EBV T cells naturally possess the following key characteristics:
Cells from donors are manufactured and stored in inventory with the goal of being readily available for patients with serious diseases
Next-generation technologies designed to:
Atara’s manufacturing technology is robust and designed to meet global regulatory standards and rapidly deliver products to patients from inventory within three days, with commercial validation activities near completion.
The Atara Research Center (ARC) houses the Company’s Translational and Pre-Clinical Sciences, Process Sciences, and Analytical Development teams. Its dedicated capabilities support our product pipeline and help drive innovation by leveraging our differentiated allogeneic cell therapy platform.
Our Fitzsimons facility in Denver is our hub for Process Development and Quality Control, with its capabilities facilitating the development, scale up, tech transfer and optimization of Atara’s advanced manufacturing processes for allogeneic cell therapies. In addition, select lot release testing of Atara’s drug products are performed at the site.